Guiding Gene Editing to Deliver Precision Based Immunotherapeutics

  • 840

    Total views and downloads

About this Research Topic

Submission deadlines

  1. Manuscript Submission Deadline 31 March 2026

  2. This Research Topic is currently accepting articles.

Background

Gene editing is a powerful technique which opens the possibility of genetic therapies which can rectify mutations which normally lead to disease. The use of artificial intelligence (AI) is having an increasing impact in informing the scientific community in the development of therapies and drugs. Employing gene editing to modify the immune system has the potential to both modulate immune responses to alleviate unwanted immune responses as well as enhance or target immune responses. The application of AI can add to the arsenal of developing immunotherapies by potentially providing a more targeted and informed approach to certain immunotherapeutic developments. The collection will cover applications of gene editing in modulating immune responses and manipulating the immune system in health and disease and how AI can be potentially applied to immunotherapies but also guide such developments.

Gene editing and AI and their application and potential interplay can provide and guide precision to immunotherapies. Reversing unwanted immune responses or preventing their activation are key in driving therapies to alleviate autoimmunity. On the flip side, the goal of vaccinology and its application to cancer immunotherapies is to activate effective specific immune responses that can specifically eradicate tumour cells as well as establish immune memory. Though biologics have come a long way regarding therapeutic interventions, we still have not tackled the causes of autoimmunity and cancer vaccines remain limited. The central driver in understanding how to overcome these clinical manifestations is antigen processing and presentation. Gene editing and AI can potentially tackle these issues, allowing us to harness the immune system without the need for long term medication. Therefore, this issue will explore how these technologies can be employed to allow us to reach the holy grails with intervention strategies in each of these immune mediated treatments.

We welcome manuscripts focusing on, but not limited to, the following sub-topics:

• Targeting T cells in autoimmunity using gene editing

• Targeting the MHC – review – gene editing the MHC

• Personalized vaccines using gene editing and AI - review and research article

• Gene editing targeting autoimmunity – research article

• AI guided antibody therapies -review

• mRNA cancer vaccines – can they be guided by gene editing and AI -review

• Small molecule targeting of antigen processing and presentation machinery in precision immunology

• AI-based vaccine design and precision immunotherapy


Topic editor Anthony W Purcell is an advisor to Evaxion Biotech. All other Topic Editors declare no competing interests with regards to the Research Topic subject.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

  • Case Report
  • Classification
  • Clinical Trial
  • Editorial
  • FAIR² Data
  • General Commentary
  • Hypothesis and Theory
  • Methods
  • Mini Review

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Keywords: CRISPR/Cas, MHC, Artificial Intelligence, Autoimmunity, Cancer Vaccines, Immunotherapies

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic editors

Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.

Impact

  • 840Topic views
View impact